[go: up one dir, main page]

WO1998041648A3 - Target genes for allele-specific drugs - Google Patents

Target genes for allele-specific drugs Download PDF

Info

Publication number
WO1998041648A3
WO1998041648A3 PCT/US1998/005419 US9805419W WO9841648A3 WO 1998041648 A3 WO1998041648 A3 WO 1998041648A3 US 9805419 W US9805419 W US 9805419W WO 9841648 A3 WO9841648 A3 WO 9841648A3
Authority
WO
WIPO (PCT)
Prior art keywords
allele
target genes
genes
loh
loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/005419
Other languages
French (fr)
Other versions
WO1998041648A2 (en
WO1998041648A9 (en
Inventor
David Housman
Fred D Ledley
Vincent P Stanton Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvelo Inc
Original Assignee
Variagenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variagenics Inc filed Critical Variagenics Inc
Priority to AU67643/98A priority Critical patent/AU6764398A/en
Priority to EP98912974A priority patent/EP0973935A2/en
Priority to CA002283636A priority patent/CA2283636A1/en
Publication of WO1998041648A2 publication Critical patent/WO1998041648A2/en
Publication of WO1998041648A9 publication Critical patent/WO1998041648A9/en
Publication of WO1998041648A3 publication Critical patent/WO1998041648A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G01N33/575—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This disclosure concerns genetic targets which have been found to be useful for allele specific anti-tumor therapy. The strategy for such therapy involves the steps of: (1) identification of alternative alleles of genes coding for proteins essential for cell viability or cell growth and the loss of one of these alleles in cancer cells due to loss of heterozygosity (LOH) and (2) the development of inhibitors with high specificity for the single remaining alternative allele of the essential gene retained by the tumor cell after LOH. Particular categories of appropriate target genes are described, along with specific exemplary genes within those categories and methods of using such target genes.
PCT/US1998/005419 1997-03-20 1998-03-19 Target genes for allele-specific drugs Ceased WO1998041648A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU67643/98A AU6764398A (en) 1997-03-20 1998-03-19 Target genes for allele-specific drugs
EP98912974A EP0973935A2 (en) 1997-03-20 1998-03-19 Target genes for allele-specific drugs
CA002283636A CA2283636A1 (en) 1997-03-20 1998-03-19 Target genes for allele-specific drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4105797P 1997-03-20 1997-03-20
US60/041,057 1997-03-20

Publications (3)

Publication Number Publication Date
WO1998041648A2 WO1998041648A2 (en) 1998-09-24
WO1998041648A9 WO1998041648A9 (en) 1999-01-07
WO1998041648A3 true WO1998041648A3 (en) 1999-04-29

Family

ID=21914484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/005419 Ceased WO1998041648A2 (en) 1997-03-20 1998-03-19 Target genes for allele-specific drugs

Country Status (4)

Country Link
EP (1) EP0973935A2 (en)
AU (1) AU6764398A (en)
CA (1) CA2283636A1 (en)
WO (1) WO1998041648A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308204B2 (en) 2009-11-02 2016-04-12 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122343B1 (en) * 1998-04-27 2006-10-17 Wisconsin Alumni Research Foundation Methods to alter levels of a DNA repair protein
US7074902B1 (en) 1998-04-27 2006-07-11 Warf Wisconsin Alumni Research Foundation Antibody specific for a DNA repair protein
GB9828840D0 (en) * 1998-12-30 1999-02-17 Univ Nottingham Trent Prostate cancer associated genes and their products
WO2001018542A2 (en) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
US6309882B1 (en) 1999-09-10 2001-10-30 Isis Pharmaceuticals, Inc. Antisense inhibition of replication protein a p70 subunit
NZ518236A (en) * 1999-09-14 2004-02-27 Scripps Research Inst Novel cell cycle checkpoint genes and proteins encoded by human Mus81 gene, holliday junction resolvase
WO2001036686A2 (en) * 1999-11-15 2001-05-25 University Of Southern California Genomic polymorphism for predicting therapeutic response
AU1939601A (en) * 1999-12-01 2001-06-12 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US20030092601A1 (en) * 1999-12-07 2003-05-15 Hanan Polansky Microcompetition and human disease
GB0000995D0 (en) * 2000-01-18 2000-03-08 Zeneca Ltd Methods
AU2001290761A1 (en) * 2000-09-08 2002-03-22 Eos Biotechnology, Inc. Methods of diagnosing breast cancer and screening for modulators
US7049059B2 (en) 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7005278B2 (en) 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
US6956111B2 (en) 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
CN102151261A (en) 2003-06-20 2011-08-17 尼瑞斯药品公司 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
WO2005068616A2 (en) 2004-01-16 2005-07-28 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinases
EP1800695A1 (en) * 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA-constructs
CN101360998B (en) 2005-12-30 2015-12-02 泛塔纳医药系统公司 Na+, K+ adenosine triphosphate expression of enzymes in cervical atypical hyperplasia and cervical carcinoma
US7704967B2 (en) 2006-03-14 2010-04-27 University Of Maryland, Baltimore TFIIS and GDOWN1 as targets for cancer therapy
US8445200B2 (en) 2009-04-15 2013-05-21 The Regents Of The University Of California Genotoxicity as a biomarker for inflammation
EP3603678A3 (en) * 2011-12-14 2020-07-29 The Board of Regents of the University of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
WO2013174859A1 (en) * 2012-05-22 2013-11-28 Centre Leon Berard Screening methods for identifying compounds which interfere with coup-tfii (nr2f2) or coup-tfi (nr2f1)
US9828641B2 (en) 2013-08-01 2017-11-28 The Regents Of The University Of California Systemic genotoxicity as blood marker for allergic inflammation
EP3096770A4 (en) * 2014-01-16 2017-12-06 Rowan University Modulation of cellular localization of cyclin c
EP3775206A1 (en) * 2018-03-28 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
CN120173770A (en) * 2025-05-21 2025-06-20 南京工业大学 A genetically engineered strain with high yield of 3'-deoxyadenosine and its application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011494A1 (en) * 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
WO1995003335A1 (en) * 1993-07-26 1995-02-02 K.O. Technology, Inc. Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents
US5491064A (en) * 1992-07-17 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services HTS-1 gene, a human tumor suppressor gene
WO1997004087A1 (en) * 1995-07-18 1997-02-06 Guido Krupp Ribozymes for the selective inhibition of expression by mhc allele genes, and drugs containing such ribozymes
WO1997032024A1 (en) * 1996-03-01 1997-09-04 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Allele suppression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491064A (en) * 1992-07-17 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services HTS-1 gene, a human tumor suppressor gene
WO1994011494A1 (en) * 1992-11-09 1994-05-26 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
WO1995003335A1 (en) * 1993-07-26 1995-02-02 K.O. Technology, Inc. Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents
WO1997004087A1 (en) * 1995-07-18 1997-02-06 Guido Krupp Ribozymes for the selective inhibition of expression by mhc allele genes, and drugs containing such ribozymes
WO1997032024A1 (en) * 1996-03-01 1997-09-04 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Allele suppression

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308204B2 (en) 2009-11-02 2016-04-12 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9439902B2 (en) 2009-11-02 2016-09-13 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9439901B2 (en) 2009-11-02 2016-09-13 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US11834697B2 (en) 2017-09-15 2023-12-05 Oxford University Innovation Limited Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria

Also Published As

Publication number Publication date
CA2283636A1 (en) 1998-09-24
EP0973935A2 (en) 2000-01-26
WO1998041648A2 (en) 1998-09-24
AU6764398A (en) 1998-10-12

Similar Documents

Publication Publication Date Title
WO1998041648A3 (en) Target genes for allele-specific drugs
Petryk et al. Staying true to yourself: mechanisms of DNA methylation maintenance in mammals
Bestor The DNA methyltransferases of mammals
Jungmann et al. Resistance to cadmium mediated by ubiquitin-dependent proteolysis
Zhang et al. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails
WO1999035170A8 (en) Compositions and methods for the treatment of tumor
Vogel et al. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes
Kaneda et al. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers
Eleveld et al. Engineering large-scale chromosomal deletions by CRISPR-Cas9
WO1999014327A3 (en) Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
US20220307012A1 (en) Endonuclease-barcoding
EP1953229A3 (en) Metastatic breast and colon cancer regulated genes
Tai et al. High-throughput loss-of-heterozygosity study of chromosome 3p in lung cancer using single-nucleotide polymorphism markers
WO2001009189A3 (en) Compositions and methods for the treatment of tumors
O'connor An alkaline deoxyribonuclease from rat liver non-histone chromatin proteins
WO1994012881A3 (en) A method for detecting growing cells using translationally controlled tumor protein p21
WO2003008578A3 (en) Reagents and methods for identifying gene targets for treating cancer
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
WO2001019966A3 (en) Isolation of muscle-derived stem cells and uses therefor
WO2000015666A3 (en) Compositions and methods for the treatment of tumors
Ikehata et al. Distribution of spontaneous CpG‐associated G: C→ A: T mutations in the lacZ gene of Muta™ mice: Effects of CpG methylation, the sequence context of CpG sites, and severity of mutations on the activity of the lacZ gene product
EP1020529A3 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
WO2000008157A3 (en) Human anion transporter genes atnov
WO2005033139A3 (en) Novel calcium channels and uses thereof
EP0859059A3 (en) Methods and materials for introducing exogenous genes into cultured cells or fertilized eggs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1-333, DESCRIPTION, REPLACED BY NEW PAGES 1-333; PAGES 334-389, CLAIMS, REPLACED BY NEW PAGES334-389; PAGES 1/214-214/214, DRAWINGS, REPLACED BY NEW PAGES 1/249-249/249; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2283636

Country of ref document: CA

Ref country code: CA

Ref document number: 2283636

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 67643/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998912974

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998912974

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998540801

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1998912974

Country of ref document: EP